CLINICAL SCIENCES Intraorbital Injection of （临床科学眶注入升高）.pdfVIP

CLINICAL SCIENCES Intraorbital Injection of Triamcinolone Acetonide in Patients With Idiopathic Orbital Inflammation Igal Leibovitch, MD; Venkatesh C. Prabhakaran, MS, MRCOphth; Garry Davis, FRANZCO; Dinesh Selva, FRANZCO Objective: To present findings of a pilot study on in- traocular pressure, blood pressure, and serum glucose traorbital corticosteroid therapy in the management of levels were measured at each visit. idiopathic orbital inflammation. Results: Ten patients (5 men and 5 women; mean age, 49.8 years [age range, 25-82 years]) received treatment. Methods: This prospective, noncomparative, interven- In 4 patients, an orbital mass was noted; in 6 patients, tional case series included patients with clinically, ra- the lacrimal gland was involved (dacryoadenitis). Sub- diologically, and histologically confirmed idiopathic or- stantial improvement (1 patient) or complete resolu- bital inflammation with an anterior orbital mass. Twenty tion (8 patients) was noted during a follow-up of 9.8 to 40 mg/mL of triamcinolone acetonide was injected in- months (range, 3-24 months). traorbitally (intralesionally or perilesionally) in all pa- Conclusion: Intraorbital injection of a corticosteroid is an tients. The injection was repeated at 4-week intervals if effective treatment for idiopathic orbital inflammation and complete resolution was not achieved. Patients were as- may be considered first-line treatment in selected patients. sessed for local and systemic complications of cortico- steroid injection. Visual acuity, fundus examination, in-